The heart failure syndrome has first been described as an emerging epidemic about 25
years ago. Today, because of a growing and ageing population, the total number of heart …

Remarkable recent advances have revolutionized the field of heart failure. Survival has
improved among individuals with heart failure and a reduced ejection fraction and for the …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Background The aims of this study were to:(i) report the baseline characteristics of patients
enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA …

Heart failure (HF) is a growing public health issue. As many as 1 in 5 people are expected to
develop HF during their lifetime, 1 with an estimated 63 million people affected worldwide. 2 …

Background: Major gaps exist in the routine initiation and dose up-titration of guideline-
directed medical therapies (GDMT) for patients with heart failure with reduced ejection …

Given the high risk of adverse outcomes in patients with heart failure and reduced ejection
fraction (HFrEF), there is an urgent need for the initiation and titration of guideline-directed …

Rationale & Objective Renin-angiotensin-aldosterone system (RAAS) inhibitors are
evidence-based therapies that slow the progression of chronic kidney disease (CKD) but …

Global Variations in Heart Failure Etiology, Management, and Outcomes - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …

Aims To assess the association between combination, dose and use of current guideline‐
recommended target doses (TD) of renin–angiotensin system inhibitors (RASi), angiotensin …